As of June 8, 2025, Shanghai RAAS Blood Products Co Ltd (002252.SZ) reports a Forward P/E of 16.42.
Forward P/E gauges the price investors pay for each dollar of anticipated earnings, offering insight into a stock's future valuation.
Comparing Shanghai RAAS Blood Products Co Ltd's Forward P/E to Peers
To better understand Shanghai RAAS Blood Products Co Ltd's position, it's useful to compare its Forward P/E against industry peers. Below are selected comparisons:
| Company | Forward P/E |
|---|---|
| Shanghai RAAS Blood Products Co Ltd (002252.SZ) | 16.42 |
| Sunshine Guojian Pharmaceutical Shanghai Co Ltd (688336.SS) | 108.98 |
| BrightGene Bio-Medical Technology Co Ltd (688166.SS) | 83.33 |
| Beijing Balance Medical Technology Co Ltd (688198.SS) | 72.50 |
| Gan & Lee Pharmaceuticals (603087.SS) | 45.61 |
| Yantai Dongcheng Biochemicals Co Ltd (002675.SZ) | 43.89 |
Compared to its competitors, Shanghai RAAS Blood Products Co Ltd's Forward P/E is among the lowest compared to peers, which may suggest undervaluation or market concerns about future earnings.